New pancreatic cancer drug Rasonque posts $198M sales in Q3, far exceeding forecasts.

Revolution Medicines' new pancreatic cancer drug, Rasonque, achieved $198 million in sales in its first full quarter after FDA approval in August, vastly surpassing the $24.9 million expected. This strong start positions the drug for an estimated $527 million in sales in Q4 and $3.1 billion next year, marking it as potentially one of the best oncology drug launches ever. The high demand highlights the drug's significant market impact and potential to improve pancreatic cancer treatment options.

As of Nov 05, 2026 23:21 WIB, Revolution Medicines Inc. (RVMD) trades on Pluang at USD 187.88, down 5.92% for the day, with a market cap of $42.80 billion. Despite the recent strong sales performance of its pancreatic cancer drug Rasonque, the stock is experiencing a notable pullback in price. The enterprise value stands at $39.51 billion, reflecting significant investor interest in the company's growth potential.